Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $2.39 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $3.65 million and the lowest is $440,000.00. BioCryst Pharmaceuticals reported sales of $3.89 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 38.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $20.31 million for the current year, with estimates ranging from $18.36 million to $21.57 million. For the next financial year, analysts forecast that the company will post sales of $13.69 million, with estimates ranging from $8.67 million to $21.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow BioCryst Pharmaceuticals.
BCRX has been the subject of a number of analyst reports. Zacks Investment Research cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 15th. BidaskClub raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 16th. Piper Jaffray Companies initiated coverage on BioCryst Pharmaceuticals in a report on Friday, November 16th. They set an “overweight” rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada lifted their price objective on BioCryst Pharmaceuticals to $16.00 and gave the company a “positive” rating in a report on Tuesday, December 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $12.18.
Shares of NASDAQ BCRX traded up $0.15 during midday trading on Monday, reaching $9.24. 433,000 shares of the company traded hands, compared to its average volume of 687,439. The stock has a market cap of $996.63 million, a PE ratio of -11.85 and a beta of 1.89. BioCryst Pharmaceuticals has a 12 month low of $4.53 and a 12 month high of $9.95. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.98 and a current ratio of 2.00.
In other news, VP Alane P. Barnes sold 44,290 shares of the firm’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $9.07, for a total value of $401,710.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas R. Staab II sold 11,198 shares of the firm’s stock in a transaction on Tuesday, November 20th. The shares were sold at an average price of $8.67, for a total value of $97,086.66. Following the completion of the sale, the insider now owns 137,458 shares of the company’s stock, valued at $1,191,760.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 143,868 shares of company stock valued at $1,283,791. 4.50% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in the company. Baker BROS. Advisors LP increased its stake in shares of BioCryst Pharmaceuticals by 7.8% in the third quarter. Baker BROS. Advisors LP now owns 15,103,081 shares of the biotechnology company’s stock valued at $115,237,000 after buying an additional 1,090,909 shares in the last quarter. Janus Henderson Group PLC increased its position in BioCryst Pharmaceuticals by 10.4% in the third quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock worth $93,469,000 after purchasing an additional 1,153,978 shares during the period. BlackRock Inc. increased its position in BioCryst Pharmaceuticals by 0.9% in the fourth quarter. BlackRock Inc. now owns 8,849,427 shares of the biotechnology company’s stock worth $71,413,000 after purchasing an additional 79,571 shares during the period. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 9.2% in the third quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after purchasing an additional 490,319 shares during the period. Finally, Vanguard Group Inc increased its position in BioCryst Pharmaceuticals by 9.2% in the third quarter. Vanguard Group Inc now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after purchasing an additional 490,319 shares during the period. Institutional investors own 91.17% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
See Also: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.